[News] San Antonio Breast Cancer Symposium 2025

In the phase 3 IidERA trial presented by Aditya Bardia (University of California Los Angeles, Los Angeles, CA, USA), adjuvant giredestrant, an oral selective oestrogen receptor degrader (SERD) showed significant improvement in invasive disease-free survival (iDFS) compared with standard-of-care endocrine therapy in patients with early-stage HR+ HER2– breast cancer. 4170 patients were randomly assigned (1:1) to receive either 30 mg…